W
WAVEMAN · COMPANY
ABT · Abbott Laboratories
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ABT

ABBOTT LABORATORIES
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000001800
CLUSTER · 3 INSIDERSC-SUITE BUYING · 1CONGRESS · 4FORM 144 · 3☆ WATCH
INSIDER NET · 180D
-$45.5M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
4
FUNDS ADDED · QTR
1,262
13F, latest reported quarter
REVENUE GROWTH
+5.7%
XBRL, annual
NET MARGIN
14.7%
CONVERSIONS · 180D
2
codes C/M, not in net · $21.5M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$45.5M over 180 days
-$46.9M over 90 days
below 94% of Pharma & Biotech
CONGRESS
4 members bought in the last year
more than 95% of Pharma & Biotech
FUNDS
1,262 funds added or opened last quarter
more than 99% of Pharma & Biotech
REVENUE
+5.7% year over year
more than 55% of Pharma & Biotech
MARGIN
14.7% net margin
more than 85% of Pharma & Biotech
BUYBACKS
$180.0M repurchased, FY to 2026-03-31
more than 75% of Pharma & Biotech
SHORT
1.3% of shares outstanding short · 1.7 days to cover · settled 2026-07-31
below 69% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$45.5M across 3 people in 180 days.
1,262 funds added or opened positions in the latest 13F quarter, of 2,973 holders.
4 members of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -15.7%
-15.7%12M
-36%-23%-9%+4%2025-092025-102025-122026-032026-052026-072026-09 2026-08-25 · Ford Robert B sold $25.3M2026-08-25 · Ford Robert B sold $20.9M2026-01-23 · Ford Robert B bought $2.0M2026-04-27 · STARKS DANIEL J bought $926.5K2026-08-11 · Morrone Louis H. sold $642.5K2026-02-04 · STARKS DANIEL J bought $545.2K2026-02-04 · STARKS DANIEL J bought $542.1K2025-11-25 · Shroff Eric sold $203.0K2026-04-23 · Boudreau Philip P bought $201.3K2026-05-07 · Stratton John G bought $173.6K2026-03-02 · Morrone Louis H. sold $132.2K2026-03-02 · Salvadori Daniel Gesua Sive sold $102.3K2026-03-02 · Shroff Eric sold $81.9K2026-03-02 · Moreland Mary K sold $70.9K2026-03-02 · MCCOY JOHN A. JR. sold $67.6K2026-03-02 · Cushman Elizabeth C. sold $30.4K2026-09-02 · MCCOY JOHN A. JR. sold $3.0K2026-09-02 · John A. McCoy, Jr. filed to sell $3.0K2026-08-25 · Robert B. Ford filed to sell $46.2M2026-08-11 · Louis H. Morrone filed to sell $642.5K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $45.5M sold by insiders over 180 days, 1,262 funds added last quarter, 4 Congress member(s) bought in 12 months, $46.8M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ABBOTT LABORATORIES insiders sold a net $45.5M of stock across 137 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
MCCOY JOHN A. JR.
VICE PRESIDENT AND CONTROLLER
SELL
2026-09-02
27.0
$3.0K
Ford Robert B
CHAIRMAN AND CEO
SELL
2026-08-25
218,535.0
$25.3M
Ford Robert B
CHAIRMAN AND CEO
SELL
2026-08-25
180,297.0
$20.9M
Morrone Louis H.
EXECUTIVE VICE PRESIDENT
SELL
2026-08-11
5,850.0
$642.5K
Stratton John G
Director
BUY
2026-05-07
2,000.0
$173.6K
137 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 132 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
152,563,476.0 sh
$13.8B
VANGUARD CAPITAL MANAGEMENT LLC
113,750,994.0 sh
$10.3B
STATE STREET CORP
80,926,234.0 sh
$7.3B
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
59,674,507.0 sh
$5.4B
Sixth Street Partners Management Company, L.P.
59,674,507.0 sh
$5.4B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
John A. McCoy, Jr.
FILED 2026-09-02
$3.0K
Robert B. Ford
FILED 2026-08-25
$46.2M
Louis H. Morrone
FILED 2026-08-11
$642.5K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
iShares U.S. Medical Devices ETF
$538.9M POSITION · AS OF 2026-03-31
17.0%
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$4.1M POSITION · AS OF 2026-03-31
5.6%
Select Medical Technology and Devices Portfolio
$178.0M POSITION · AS OF 2026-02-28
4.9%
DIAMOND HILL SELECT FUND
$26.1M POSITION · AS OF 2026-03-31
4.6%
DIAMOND HILL LARGE CAP FUND
$171.5M POSITION · AS OF 2026-03-31
4.4%
Invesco Pharmaceuticals ETF
$14.0M POSITION · AS OF 2026-04-30
4.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Government contracts
USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue
Department Of Veterans Affairs
CHEMICAL ANALYZER · 2022-02-11
$10.1M
Department Of Veterans Affairs
COST PER REPORTABLE RESULT VA PUGET SOUND HEALTH CARE SYSTEM · 2020-12-01
$5.7M
FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Abbott Laboratories Employee Political Action Committee
CYCLE 2026 · $1,651K SPENT
$1.5M
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Robert B. Ford
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$24.2M
$26.8M
$7.5M
+25%
+48%
2024
$22.8M
$24.8M
$7.4M
+42%
+47%
2023
$23.3M
$20.5M
$6.2M
+36%
+43%
2022
$21.7M
$8.0M
$7.4M
+33%
+40%
2021
$24.9M
$43.3M
$9.3M
+67%
+43%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$44.3B$42.0B$40.1B$43.7B
OPERATING INCOME$8.1B$6.8B$6.5B$8.4B
NET INCOME$6.5B$13.4B$5.7B$6.9B
EPS (DILUTED)3.727.643.263.91
OPERATING CASH FLOW$9.6B$8.6B$7.3B$9.6B
CASH$8.5B$7.6B$6.9B$9.9B
LONG-TERM DEBT$9.9B$12.6B$13.6B$14.5B
BUYBACKS$893.0M$1.3B$1.2B$3.8B
DIVIDENDS PAID$4.1B$3.8B$3.6B$3.3B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →